EP. 1: Extensive-Stage Small Cell Lung Cancer Treatment Landscape
In March 2019, the FDA approved the combination regimen of atezolizumab, an anti‑programmed death‑ligand 1 (PD‑L1) monoclonal antibody, with carboplatin and etoposide for the frontline treatment of patients with extensive‑stage small‑cell lung cancer.
This article reviews treatment options for extensive‑stage small‑cell lung cancer (ES‑SCLC), focusing on recent FDA approvals of atezolizumab and durvalumab in combination with carboplatin or cisplatin plus etoposide, and discusses the clinical impact of chemotherapy‑induced myelosuppression.
The approval of atezolizumab + carboplatin/etoposide represents a pivotal shift from platinum‑etoposide alone to an immunotherapy‑based regimen as first‑line therapy for extensive‑stage SCLC, providing a statistically significant survival benefit in the IMpower133 phase‑3 trial.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells